Prostate cancer: Assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI Journal Article


Authors: Hötker, A. M.; Mazaheri, Y.; Zheng, J.; Moskowitz, C. S.; Berkowitz, J.; Lantos, J. E.; Pei, X.; Zelefsky, M. J.; Hricak, H.; Akin, O.
Article Title: Prostate cancer: Assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI
Abstract: Purpose: To investigate the effects of androgen-deprivation therapy (ADT) on MRI parameters and evaluate their associations with treatment response measures. Materials and methods: The study included 30 men with histopathologically confirmed prostate cancer who underwent MRI before and after initiation of ADT. Thirty-four tumours were volumetrically assessed on DW-MRI (n = 32) and DCE-MRI (n = 18), along with regions of interest in benign prostatic tissue, to calculate apparent diffusion coefficient (ADC) and transfer constant (Ktrans) values. Changes in MRI parameters and correlations with clinical parameters (change in prostate-specific antigen [PSA], treatment duration, PSA nadir) were assessed. Results: Prostate volume and PSA values decreased significantly with therapy (p < 0.001). ADC values increased significantly in tumours and decreased in benign prostatic tissue (p < 0.05). Relative changes in ADC and absolute post-therapeutic ADC values differed significantly between tumour and benign tissue (p < 0.001). Ktrans decreased significantly only in tumours (p < 0.001); relative Ktrans changes and post-therapeutic values were not significantly different between tumour and benign tissue. The relative change in tumour ADC correlated significantly with PSA decrease. No changes were associated with treatment duration or PSA nadir. Conclusions: Multi-parametric MRI shows significant measurable changes in tumour and benign prostate caused by ADT and may help in monitoring treatment response. Key Points: • Androgen-deprivation therapy caused changes of ADC, Ktransin tumour and benign prostate. • Prostate volume and PSA values decreased significantly with therapy. • ADC values may be helpful for monitoring treatment response. © 2015, European Society of Radiology.
Keywords: adult; clinical article; controlled study; human tissue; treatment response; aged; histopathology; treatment duration; nuclear magnetic resonance imaging; prostate specific antigen; prostate cancer; quantitative analysis; gonadorelin derivative; androgen deprivation therapy; diffusion weighted imaging; dynamic contrast-enhanced mri; diffusion coefficient; prostate size; nuclear magnetic resonance scanner; androgen receptor antagonist; dynamic contrast enhanced magnetic resonance imaging; human; male; priority journal; article; diffusion mri
Journal Title: European Radiology
Volume: 25
Issue: 9
ISSN: 0938-7994
Publisher: Springer  
Date Published: 2015-09-01
Start Page: 2665
End Page: 2672
Language: English
DOI: 10.1007/s00330-015-3688-1
PROVIDER: scopus
PMCID: PMC4530043
PUBMED: 25820537
DOI/URL:
Notes: Export Date: 2 September 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Junting Zheng
    200 Zheng
  2. Michael J Zelefsky
    754 Zelefsky
  3. Chaya S. Moskowitz
    279 Moskowitz
  4. Hedvig Hricak
    420 Hricak
  5. Oguz Akin
    264 Akin
  6. Xin Pei
    134 Pei
  7. Andreas Markus Hoetker
    22 Hoetker
  8. Joshua Lantos
    5 Lantos